Travera announces publication of groundbreaking clinical data from their disruptive Rapid Therapy Selection (RTS) Test ™
A cutting-edge study titled "Cellular Mass Response to Therapy Correlates with Clinical Response for a Range of Malignancies" has been published in the Journal of Clinical Oncology Precision Medicine, shedding light on a promising and potentially disruptive approach to cancer therapy... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 22, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
Bugs as Drugs to Boost Cancer Therapy
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks. (Source: The Scientist)
Source: The Scientist - January 18, 2024 Category: Science Tags: News News & Opinion Source Type: news
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 42nd Annual... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 2, 2024 Category: Pharmaceuticals Tags: FVT TDS Source Type: news
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 42,000 restricted stock units (RSUs) to one newly-hired employee. This RSU award... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 2, 2024 Category: Pharmaceuticals Source Type: news
US FDA puts clinical hold on Iovance's cancer therapy trial
(Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push
(Source: Reuters: Health)
Source: Reuters: Health - December 27, 2023 Category: Consumer Health News Source Type: news
AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
Gracell Biotechnologies acquisition marks China ’s growing importance to the Anglo-Swedish drugmakerAstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn ( £950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market.The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient ’s cells to fight the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 26, 2023 Category: Science Authors: Kalyeena Makortoff Tags: AstraZeneca Mergers and acquisitions UK news Business Pharmaceuticals industry Health Medical research Cancer Cancer research China Asia Pacific World news Source Type: news
Metastatic Breast Cancer Treatment: What the Future Holds Metastatic Breast Cancer Treatment: What the Future Holds
Dr Eric Winer discusses the current state of metastatic breast cancer therapies and what the future holds, as clinicians strive to optimize patient care.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2023 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news
Checkpoint Therapeutics Slides After US FDA Declines Cancer Therapy Approval Checkpoint Therapeutics Slides After US FDA Declines Cancer Therapy Approval
Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Precision Medicine: A New Era in Cancer Therapy
Precision medicine helps clinicians tailor individual treatments, addressing genetic mutations, tumor microenvironment variations, and therapeutic resistance. (Source: The Scientist)
Source: The Scientist - December 15, 2023 Category: Science Tags: The Scientist University Sponsored Article Source Type: news
CytoImmune Therapeutics Expands Phase 1 Trial of CYTO-102
Phase 1 study of CYTO-102 with atezolizumab (Tecentriq®) at Chan Soon-Shiong Institute for Medicine pioneers new avenues in cancer therapy TOA BAJA, Puerto Rico, Dec. 14, 2023 /PRNewswire-PRWeb/ -- CytoImmune Therapeutics announces today a significant extension of its ongoing Phase 1... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 14, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Endometrial Cancer Therapy Combo Fails 1L Treatment Trial Endometrial Cancer Therapy Combo Fails 1L Treatment Trial
Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
